Posters
Aflibercept vs bevacizumab combined with phacoemulsification in patients with diabetic macular edema
Poster Details
First Author: M.Zivkovic SERBIA
Co Author(s):
Abstract Details
Purpose:
To compare the effects of the combination of aflibercept and phacoemulsification with the combination of bevacizumab and phacoemulsification on clinically significant diabetic macular edema in patients with non-proliferative diabetic retinopathy.
Setting:
The study was performed at the Ophthalmology Eye Hospital-Clinic Maja, Nis, Serbia.
Methods:
The study included 21 patients with clinically significant DME who underwent combined phacoemulsification with 2mg dose of intravitreal aflibercept and 23 patients also with clinically significant DME who underwent the procedure of combined phacoemulsification and intravitreal bevacizumab application. Control medical check-ups included visual acuity (BCVA) and intraocular pressure measurements, fundus examination using Visucam 500 fundus camera, and macular OCT (optical coherence tomography) obtained with the Cirrus SD OCT device (Carl Zeiss Meditec, Dublin, CA, USA). Check-up examinations were performed at postoperative day 7, and then after one and three months.
Results:
Anatomical, as well as functional improvement was significant in both groups of patients. In the group of patients who received aflibercept preoperative central foveal thickness was 483+105.23 and after 3 months 305+133.42. In the group of patients who received bevacizumab preoperative central foveal thickness was 475+101.76 and after 3 months 320+130.78. In the group of patients who were treated with aflibercept, less reinjections were registered.
Conclusions:
The combination of phacoemulsification and intravitreal application of aflibercept and bevacizumab is a safe treatment option in patients with diabetic macular edema and cataract. Both drugs are equally efficient. The number of reinjections is lower in the application of aflibercept.
Financial Disclosure:
NONE
